Abstract
Sturti / Getty Images
Precision medicine platform company 2bPrecise, launched in December its pharmacogenomics (PGx) solution, leveraging the clinical decision support capabilities of Translational Software Inc.'s (TSI) PGx data content.
“As medicine becomes increasingly personalized, providers are turning to pharmacogenomics as a powerful first step into precision medicine to improve treatment effectiveness,” said Bob Robke, vice president of 2bPrecise. “By offering an easy-to-use solution that plugs into existing workflows with minimal effort, an organization can achieve immediate benefits that can then scale to the growing need for additional molecular decision support.”
2bPrecise partnered with TSI to leverage its knowledgebase of actively curated, evidence-based content, which provides clinicians with genotyping prompts; genomic decision support; and alerts regarding drug efficacy, toxicity; and known interactions to guide clinical decision making.
“What's exciting about our partnership with 2bPrecise is that its technology pushes live, real-time PGx content beyond the lab, directly into the clinical setting. PGx data is no longer limited to a static interpretation at the time of result, allowing delivery of rich genomic insights to clinicians for more precisely diagnosing and treating their patients,” added Don Rule, founder and CEO of TSI.